Cambrium Launches NovaColl™: First Micro-Molecular & Skin-Identical Collagen Ingredient for Personal Care Industry
23 Mar 2023
BERLIN, March 23, 2023 (GLOBE NEWSWIRE) -- Biotechnology company Cambrium has launched its first product: NovaColl™. It is the first micro-molecular & 100% skin-identical collagen specifically designed for premium personal care formulations.
Owing to its structure and small molecular size, NovaColl™ is able to create powerful collagen benefits across skin layers. This new class of collagen active is vegan certified and produced through Cambrium’s precision fermentation process, offering formulators a unique combination of efficacy, skin-compatibility and sustainability.
NovaColl™’s claims have been scientifically validated in third party in vitro studies, which demonstrated a broad range of activities working to holistically protect, maintain and enhance native collagen.
Beyond bio-similarity, NovaColl™ is 100% skin-identical, offering previously inaccessible levels of biocompatibility for personal care applications. To achieve this, Cambrium’s multi-disciplinary team of scientists and engineers searched through billions of protein sequences for skin-active features and indicators of efficacy. They identified NovaColl™, a highly bioactive region of collagen I, the most prevalent collagen type in our human skin.
Rather than extracting collagen from animals, Cambrium uses yeast cells to grow their micro-molecular collagen in a cruelty-free and sustainable fermentation process, minimizing energy, land, and water use.
Cambrium will exhibit at booth AK84 at the in-cosmetics Global trade show from March 28-30 in Barcelona, Spain. For more information about NovaColl™ and to request a meeting, please write to novacoll@cambrium.bio.
About Cambrium
Cambrium’s mission is to trigger the next wave of sustainable product innovation through the creation of new, high performance molecules. Using their technology-enabled molecular design platform, they discover, develop and manufacture proteins that unlock previously inaccessible functionalities. For more information, visit .
A photo accompanying this announcement is available at
NovaColl™ image
NovaColl™ product image
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.